Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer|November 1, 1987
High doses of prochlorperazine for cisplatin-induced emesis. A prospective, random, dose-response studyB I Carr, D W Blayney, D A Goldberg, et al.Gynecologic Oncology|June 1, 1993
High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensityA Bonetti, S B Howell, E McClay, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1993
Dose intensification of cisplatin chemotherapy through biweekly administrationS Kim, S B Howell, E McClay, et al.Gynecologic Oncology|May 30, 2009
Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II studyD S McMeekin, A Lisyanskaya, M Crispens, et al.British Journal of Cancer|October 1, 1993
A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposideE F McClay, R Goel, P Andrews, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicitiesD R Gandara, W A Nahhas, M D Adelson, et al.British Journal of Cancer|February 14, 2013
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trialN Colombo, D S McMeekin, P E Schwartz, et al.Gynecologic Oncology|June 1, 2000
Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-upR J Morgan, P Braly, L Leong, et al.Gynecologic Oncology|December 22, 1999
Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-upR J Morgan, P Braly, G Cecchi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2025
Dostarlimab and niraparib in primary advanced ovarian cancerA-C Hardy-Bessard, E Pujade-Lauraine, R G Moore, et al.Pageof 2